With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

Valneva (VALN) announced that the European Commission has granted marketing authorization in Europe for Valneva’s single-dose vaccine, Ixchiq, ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

The Schall Law investigates Valneva after CDC links its vaccine to hospitalizations. Investors may have legal options.

Saint Herblain, France Tuesday, April 1, 2025, 16:00 Hrs [IST] ...

Significant regulatory progress was made with IXCHIQ, including three additional approvals and ongoing label extension activities. The company expanded market access for IXCHIQ, launching in ...

This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ® label to adolescents in the European Union (EU)2. IXCHIQ® is the world’s ...